Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.77 |
| ▸ | KDR | P35968 | 5/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | STK10 | O94804 | 1/20 | 0.76 |
| ▸ | RET | P07949 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | JAK3 | P52333 | 1/20 | 0.76 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.76 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.76 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.76 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.76 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 2/20 | 0.74 |
| ▸ | FBP1 | P09467 | 6/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Whi-P131 SCHEMBL29369589 | 0.86 | EGFR (1.00) | EGFRKDRGAKRIPK2STK10 | |
| Whi-P131 SCHEMBL29295 | 0.86 | EGFR (1.00) | EGFRKDRGAKRIPK2STK10 | |
| SCHEMBL5565577 | 0.86 | FGFR1 (0.78) | EGFRKDRRETFBP1ERBB2 | |
| SCHEMBL16660323 | 0.86 | EGFR (0.77) | EGFRKDRGAKRIPK2STK10 | |
| Whi-P131 SCHEMBL6068752 | 0.85 | EGFR (1.00) | EGFRKDRGAKRIPK2STK10 | |
| SCHEMBL4469673 | 0.84 | JAK3 (0.79) | EGFRKDRRETJAK3FBP1 | |
| SCHEMBL13604740 | 0.83 | EGFR (0.66) | EGFRKDRRETLCKFBP1 | |
| SCHEMBL14979614 | 0.83 | EGFR (0.71) | EGFRKDRRETFBP1ERBB2 | |
| SCHEMBL20792806 | 0.83 | EGFR (0.87) | EGFRKDRGAKRIPK2STK10 | |
| SCHEMBL13604741 | 0.82 | EGFR (0.85) | EGFRKDRRIPK2RETLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20060276514-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276514-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | EGFR 31/4885KDR 128/4885GAK 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.